ARTICLE | Product Development
A milestone year for Roche’s CNS gambit could kick off its plan for the decade
Roche putting CNS as the growth driver of the next decade; 2020 might be the year it takes off
January 25, 2020 1:23 AM UTC
Updated on Feb 4, 2020 at 12:18 AM UTC
A ramped up focus on CNS that has been long in the making could start to pay off this year for Roche, which has two programs slated for launch and four others with late-stage readouts on the docket. The goal is to build neurology as a second crown jewel to oncology. That will mean Roche keeping its foot on the gas with partnering, as it scouts for new technologies and digital health tools that can improve patient outcomes and differentiate its portfolio.
Buysiders have already tagged neuroscience as a space ripe for new drugs and clinical data this year (see “Why Buysiders Say 2020 Could be the Year of the CNS”)...